TRPML1, a member of the mucolipin subfamily of transient receptor potential (TRPML) channels, is a mammalian endolysosomal cation-permeable channel [1] [2] [3] that is an important regulator of trafficking [4] [5] [6] and autophagy-related events 4, [7] [8] [9] . The activity of TRPML1 is regulated by the concentrations of Ca 2+ and H + in the lysosomal lumen and cytosolic space 3, 10 . TRPML1 also serves as a proton leak, responsible for preventing the excessive acidification of lysosomes 11 . It is activated by various small-molecule synthetic compounds 12, 13 (for example, mucolipin synthetic agonist 1 (ML-SA1) and MK6-83) and phosphatidylinositol-3,5-bisphosphate (PtdIns(3,5)P 2 ) 14, 15 , and is inhibited by sphingomyelins and PtdIns(4,5)P 2 16 . The transfer of Ca 2+ from the lysosomal lumen to the cytoplasm by TRPML1 is indispensable in many endolysosome-dependent cellular processes 2,3 (such as cholesterol accumulation, lipid trafficking, exocytosis and autophagy). Mutations in TRPML1 cause the neurodegenerative lysosomal storage disease mucolipidosis type IV [17] [18] [19] , which leads to cognitive, linguistic, and motor defects, and retinal degeneration 20, 21 . TRPML channels are widespread in metazoans 16, 22 . Specifically, in mammalian cells, two TRPML proteins, TRPML2 and TRPML3, share high sequence homology with TRPML1 (Extended Data Fig. 1 ). TRPML2 expression is highly restricted to lymphocytes and other types of immune cells 23 , whereas mice with gain-of-function mutations in Trpml3 present with deafness, pigmentation defects, and circling behaviour 24, 25 . Therefore, the structure of TRPML1 may further our understanding of Ca 2+ -mediated lysosomal activities, lysosome ion homeostasis, mucolipidosis type IV pathogenesis, and the functions of TRPML2 and TRPML3.
TRPML1, a member of the mucolipin subfamily of transient receptor potential (TRPML) channels, is a mammalian endolysosomal cation-permeable channel [1] [2] [3] that is an important regulator of trafficking [4] [5] [6] and autophagy-related events 4, [7] [8] [9] . The activity of TRPML1 is regulated by the concentrations of Ca 2+ and H + in the lysosomal lumen and cytosolic space 3, 10 . TRPML1 also serves as a proton leak, responsible for preventing the excessive acidification of lysosomes 11 . It is activated by various small-molecule synthetic compounds 12, 13 (for example, mucolipin synthetic agonist 1 (ML-SA1) and MK6-83) and phosphatidylinositol-3,5-bisphosphate (PtdIns(3,5)P 2 ) 14, 15 , and is inhibited by sphingomyelins and PtdIns(4,5)P 2 16 . The transfer of Ca 2+ from the lysosomal lumen to the cytoplasm by TRPML1 is indispensable in many endolysosome-dependent cellular processes 2, 3 (such as cholesterol accumulation, lipid trafficking, exocytosis and autophagy). Mutations in TRPML1 cause the neurodegenerative lysosomal storage disease mucolipidosis type IV [17] [18] [19] , which leads to cognitive, linguistic, and motor defects, and retinal degeneration 20, 21 . TRPML channels are widespread in metazoans 16, 22 . Specifically, in mammalian cells, two TRPML proteins, TRPML2 and TRPML3, share high sequence homology with TRPML1 (Extended Data Fig. 1 ). TRPML2 expression is highly restricted to lymphocytes and other types of immune cells 23 , whereas mice with gain-of-function mutations in Trpml3 present with deafness, pigmentation defects, and circling behaviour 24, 25 . Therefore, the structure of TRPML1 may further our understanding of Ca 2+ -mediated lysosomal activities, lysosome ion homeostasis, mucolipidosis type IV pathogenesis, and the functions of TRPML2 and TRPML3.
Breakthroughs in electron cryo-microscopy (cryo-EM) have accelerated structural determinations of TRP channels [26] [27] [28] [29] [30] [31] [32] [33] [34] , and provided valuable insights into the functional mechanisms and molecular dynamics of this family. Recently, structures of the human TRPML1 luminal domain have been reported 35 . This domain has a similar architecture to the polycystin domain of PKD2 32 , a member of the polycystin TRP family that, along with the TRPML channels, belongs to the group 2 TRP channel family. However, the full-length structure of TRPML1 and the mechanism of its regulation are yet to be elucidated.
Overall structure of human TRPML1
We expressed full-length human TRPML1 (580 residues) by baculovirus-mediated gene transduction of mammalian cells 36 . The protein eluted as a monodisperse peak under 0.04% (w/v) digitonin during gel filtration, with a small fraction of an N-terminally degraded fragment (Extended Data Fig. 2a) , and was subjected to structure determination by cryo-EM.
The apo TRPML1 at pH 7.0 was determined at 3.7 Å, representing a closed conformation; the ML-SA1-bound TRPML1 at pH 6.0 was determined at 3.5 Å, representing an open conformation (Extended Data Figs 2b, 3 and Extended Data Table 1 ). TRPML1 has a similar topology to other TRP channels, and forms the canonical homotetrameric assembly in which the ion channel is formed at its centre. Each subunit contains six transmembrane helices (S1-S6), two pore helices (PH1 and PH2), and a luminal domain of around 25 kDa (Fig. 1a-c) . The electron density is clearly resolved for residues 60-526 in the apo TRPML1 and residues 38-526 in the ML-SA1-bound TRPML1 (Extended Data Fig. 4) , with the exception of a short linker in the luminal domain (amino acids 206-215). The local resolution of S4-S6 is about 3.0 Å, which allowed us to build confidently the side chains of the pore region with high accuracy (Extended Data Figs 2b, 4) . Whereas the overall structure of TRPML1 is similar to that of PKD2 32 (PDB code: 5T4D; root mean square deviation = 3.8 Å), TRPML1 contains unique features: the S2 helix of TRPML1 is longer than that of PKD2 and protrudes from the membrane bilayer-embedded part into the cytosol, and the N-terminal S1 helix has an extension (pre-S1) including two small α -helices (α 1 and α 2) enriched in many basic amino acids (Extended Data Figs 1, 5) .
Our structure provides details of the interface between the transmembrane helices and the luminal domain (Fig. 1d) . Residues N97,
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-releasing cation channel that mediates the calcium signalling and homeostasis of lysosomes. Mutations in TRPML1 lead to mucolipidosis type IV, a severe lysosomal storage disorder. Here we report two electron cryo-microscopy structures of full-length human TRPML1: a 3.72-Å apo structure at pH 7.0 in the closed state, and a 3.49-Å agonist-bound structure at pH 6.0 in an open state. Several aromatic and hydrophobic residues in pore helix 1, helices S5 and S6, and helix S6 of a neighbouring subunit, form a hydrophobic cavity to house the agonist, suggesting a distinct agonist-binding site from that found in TRPV1, a TRP channel from a different subfamily. The opening of TRPML1 is associated with distinct dilations of its lower gate together with a slight structural movement of pore helix 1. Our work reveals the regulatory mechanism of TRPML channels, facilitates better understanding of TRP channel activation, and provides insights into the molecular basis of mucolipidosis type IV pathogenesis.
R102, H103 and L104 of the S1 helix form hydrogen bonds or salt bridges with Y147, D114, D111 and H131 of the luminal domain. There is an intermolecular interaction between E276 in β -strand β 7 and R486 of the PH2-S6 linker in the adjacent subunits. The S1 helical residues F93, F101, L104, F105 and L106 are buttressed against a hydrophobic area formed by the three β -strands of the luminal domain.
Structure of the TRPML1-ML-SA1 complex
ML-SA1 specifically stimulates TRPML channels without activating those of other TRP subfamilies, making it a useful molecule for studying the function of TRPML channels 12 . To investigate the activation mechanism of TRPML1, we incubated the protein with ML-SA1 at pH 6.0 before grid preparation for cryo-EM. Compared with the apo structure, we observed extra density between S5 and S6 (Extended Data Fig. 2b) . Notably, the approximately 3.0-Å local resolution in this region supports the interpretation of this density as ML-SA1 (Extended Data Figs 2b, 4). A hydrophobic cavity created by I468 and F465 of PH1; F428, C429, V432 and Y436 of S5; F505 and F513 of S6; and Y499 and Y507 of S6 in the neighbouring subunit, tightly accommodates the agonist ( Fig. 2b and Extended Data Fig. 1 ).
The agonist-binding site in TRPML1 is different to that previously reported in TRPV1, although both binding sites require two adjacent subunits of one tetramer (Fig. 2b, c) . S5, S6 and PH1 of one subunit, and S6 of the neighbouring subunit, accommodate ML-SA1 binding to TRPML1, without the involvement of the S4-S5 linker as found in TRPV1 (Fig. 2c) . This binding induces a dilation of the lower selectivity filter and lower gate in TRPML1 (as discussed later). Resiniferatoxin, an agonist of TRPV1, directly binds to an S4-S5 linker of TRPV1, the S4 helix, and the S5 and S6 helices of the neighbouring subunit without binding to the pore helices (Fig. 2c) . Interestingly, the comparable ML-SA1-binding site in TRPV1 and the voltage-gated calcium channel Ca V Ab could accommodate associated lipids 29 or the Ca V Ab antagonist UK-59811 37 ( Fig. 2c) , suggesting the possibility of this site for hosting other ligands in related ion channels.
To verify our findings, we performed whole-cell electrophysiology on cells expressing TRPML1 with mutations in the proposed agonistbinding hydrophobic cavity. To express TRPML1 at the cell surface, we used a leucine-to-alanine mutant that has been demonstrated to enrich functional plasmalemmal expression of TRPML1 (L 15 L and L 577 L to alanine residues, abbreviated as L/A; refs 12, 38). On the basis of our structural findings, we generated five individual mutants on the agonist-binding sites: C429G and Y436A in S5, F465A in PH1, and Y499A and F513A in S6. HEK293T cells were transiently transfected with TRPML1(L/A) constructs with an N-terminal enhanced GFP (eGFP) tag for selection. As reported previously 12 , application of ML-SA1 at pH 4.6 considerably activates whole-cell currents at negative potentials for TRPML1(L/A), with modest increases in current density also detected at pH 7.4 (Fig. 3a) . Intracellular application of the lipid agonist PtdIns(3,5)P 2 also generates a significant current at pH 4.6 without ML-SA1, and notably, with application of both PtdIns(3,5)P 2 and ML-SA1, the increase in current is pronounced (Fig. 3d) .
Binding pocket mutations Y436A, F465A and Y499A abrogated the ML-SA1 agonist-induced currents but failed to respond significantly to PtdIns(3,5)P 2 stimulation, suggesting loss of function of the channels (Fig. 3g) . We hypothesize that the compact structural arrangement of the pore helices was disrupted and ion efflux stopped because these mutated sites are either in, or close to, the pore helices. Notably, mutated sites C429G and F513A, away from the pore helices, demonstrated similar expression patterns to L/A (Extended Data Fig. 6c ). Like the other mutations, C429G and F513A failed to respond to ML-SA1 application (Fig. 3b, c, g ); however, a positive response to PtdIns(3,5)P 2 was observed, similar to wild-type TRPML1(L/A) (Fig. 3e, f) . We observed a significant synergistic increase in current densities for TRPML1(L/A) when PtdIns(3,5)P 2 and ML-SA1 were co-applied. For mutants C429G and F513A, this increase in current density was completely blocked (Fig. 3e-g ). This indicates functional activation of the channel by the lipid agonist PtdIns(3,5)P 2 and lack of functional binding by ML-SA1. Electrophysiological analysis functionally confirms this agonist-binding site in vitro.
Opening of the lower gate and selectivity filter
Superimposition of the apo and ML-SA1-bound TRPML1 structures does not reveal any notable changes in the luminal domains, consistent with previous research that did not identify luminal domain structural changes with varying pH 35 . The apo structure presents a closed solvent-accessible pathway (Fig. 4a ) and the ML-SA1-bound structure presents an open solvent-accessible pathway (Fig. 4b) . Importantly, a marked difference between the two structures is observed: a shift in the relative positions of PH1 and S6 (Fig. 4c) . The selectivity filters of TRPML channels are highly conserved, including a three-residue motif (GDD 472 ) (Extended Data Fig. 1 ). Upon binding to ML-SA1, the distance between the D471 Cα atoms and the distance between the G470 carbonyl oxygen atoms show no substantial change (Fig. 4c, d) ; notably, the carbonyl oxygens of N469 are 1.8 Å further apart than in the apo state (Fig. 4c) , to open the lower selectivity filter. There is no marked conformational change in M644 of TRPV1 (PDB code: 5IRZ) after the binding of capsaicin (PDB code: 3J5R) at the equivalent position in TRPML1 (that is, at D471). By contrast, the distance between carbonyl oxygens of I642 in capsaicin-bound TRPV1 increases from 8.6 Å to 10.2 Å at the equivalent position of TPRML1 (that is, at N469).
The amino acids F 505 IYMV 509 form a π -helix in the middle of S6, a highly conserved structural feature among TRP channels. We speculate that this π -helix may control the dynamics of the bottom half of S6 and open the lower gate. I514 and T518 in S6 form two constricted sites close to the cytoplasmic side that are sufficiently narrow (approximately 5.5 Å) to restrict hydrated ion flow. This observation is consistent with the lower gate of the channel PKD2 [32] [33] [34] , which uses two residues, L677 and N681, to block the conduction of hydrated ions across the gate. In the presence of ML-SA1, both constricted sites of the lower gate expand from 5.6 Å and 5.5 Å to 8.4 Å and 9.8 Å (Fig. 4c-f) , respectively. These changes in the ion permeation pathway are coupled with a slight shift of S6 away from the central channel, resulting in a wider opening of the lower gate (Fig. 4c-f) . The lower gate of TRPML1 is similar to that of TRPV1, which opens from 5.3 Å to 7.6 Å when it binds to capsaicin, or to 9.3 Å when it binds to vanillotoxin or resiniferatoxin 26, 29 . The comparison of apo versus ML-SA1-bound structures suggests a molecular mechanism of TRPML1 activation. F505 and F513, in contact with ML-SA1, force helix S6 away from the central axis, opening the lower gate (Fig. 5a ). F465 and I468 change their conformations to create a hydrophobic cavity that facilitates ML-SA1 binding. These changes, in turn, move N469 to a lower position allowing the formation of a hydrophilic interaction (at a distance of 3.5 Å) with Y507 in S6 of the neighbouring subunit, causing a slight opening of the selectivity filter (Fig. 5a) .
A proline substitution at V432 (TRPML1(V432P)) causes a gainof-function phenotype that activates TRPML1 channels at the plasma and lysosomal membranes 25, 39 . Notably, the transfection of TRPML1(V432P) into HEK293 cells appears to enhance lysosomal exocytosis 39 . In light of our structure, this gain-of-function mutation can now be rationalized in molecular detail. In the apo state, the Cα distances between V432 and V509 and between V432 and F513 are 3.9 Å and 4.7 Å, respectively, facilitating strong van der Waals interactions to maintain S6 in the closed state. The V432P mutation disrupts these hydrophobic interactions and releases S6 from S5; it may allow S6 to swing open, akin to the action of ML-SA1, which interrupts the V432-F513 interaction and triggers the lower gate to open (Fig. 5b) . Besides this putative mechanism, V432P mutation might also break S5, introducing more marked structural arrangements that result in channel opening. However, the rationale behind notably increased exocytosis and plasma membrane localization of TRPML1(V432P) requires additional work.
Summary
We report two structures of TRPML1 in distinct conformations by cryo-EM. These structures allow us to map the mutations that cause mucolipidosis type IV 3 (Extended Data Fig. 7 ). Like other lysosomal storage disease-causing proteins 40, 41 , several mutations 1 (such as T232P and D362Y) in TRPML1 lead to mislocalization and block the flow of Ca 2+ across the lysosomal membrane. A previous study identified luminal domain mutations 35 , including L106P, C166F and T232P. Other clinically defined loss-of-function mutations may be explained by our structure. For instance, aromatic-aromatic interactions between F465 in PH1 and Y499 in S6 of the neighbouring subunit could support the conformation of pore helices; the F465L mutation may disrupt this interaction and the dynamics of the selectivity filter. Y436 forms a hydrophilic interaction with S461 in PH1, potentially stabilizing the selectivity filter. Our electrophysiological experiments support the idea that Y436A, F465A and Y499A mutants could not be stimulated by agonist ML-SA1 and PtdIns(3,5)P 2 .
The ML-SA1-bound TRPML1 structure presents a novel agonist-binding site among TRP channels. Remarkably, ML-SA1 is buried in an aromatic pocket created by two TRPML1 subunits. Structural analysis reveals an allosteric coupling between the selectivity filter and the lower gate, which may explain the molecular mechanism of this channel (Fig. 5c ). The ML-SA1 agonist releases the restriction of the lower gate and induces a structural rearrangement of PH1. Both changes create a new hydrophilic bond between Y507 (S6) and N469 (PH1) of the neighbouring subunit, leading to a slight opening of the selectivity filter. Previous studies have shown that there is a PtdIns(3,5)P 2 -binding site in the positively charged pre-S1 region of TRPML1 15 , which is distant from the ML-SA1-binding site that we mapped in the membrane domain. A related Nature paper provides specific insights into TRPML1 in the lipid environment 42 . Combined with previous structural observations on TRP channels, our work suggests some commonalities of TRP channels as a whole: first, the inter-subunit agonist-binding site is found in both the TRPML and TRPV families, although these two sites are in different positions of the membrane region; and second, the lower gate in the channels of group 2 TRP family proteins have two constriction sites. Moreover, owing to the topological similarities between PKD2 and TRPML1, PKD2 may have a similar agonist-binding site, and thus our study might provide insights into the activation of PKD2 and the pathogenic mechanism of PKD2-related autosomal dominant polycystic kidney disease.
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